JAK inhibitors may be helpful for some patients with refractory adult and pediatric Still’s disease, but not in monotherapy (5 adults, 2 children, mean 11 month f/u, partial response in 4, failure in 3, steroid tapering difficult) @rheumnow #ACRbest #abst0195

Numeracy - (i.e. low health literacy) had lower self-reported adherence but paradoxically higher objective adherence in #Lupus @MithuRheum @rheumnow #ACRBest #abst0131

#ACR21 Abst#0463: Medicare claims data in ~3500 bDMARD-naive, sero+RA (avg 66 yo, 78%♀) showed those on Abatacept had longer time b4 tx stop (152d) @ 1yr vs TNFi (97d) or JAKi (89d)--is this reflective of tx efficacy? Where does ABT rank 4 u? @Rheumnow https://t.co/yfhxAsKBLl https://t.co/o84Ajmeyfk

• Treatment Persistence Among Medicare Beneficiaries with Seropositive Rheumatoid…

No effect if ⤴️LDL in #Tocilizumab on #cardiovascular events vs other bDMARDs. Nice study from Corona. Ok why would we think that minor changes in lipids in RA & improved inflammation and ⤵️CRP would affect CV events? NNH is enormous & need yrs of f/u @RheumNow #ACR21 abst0268 https://t.co/cW65PmQ61u

Wonderful review on HES vs. EGPA by Dr. Amy Klion ⭐️1st line tx still steroids ⭐️New ACR 2021 EGPA guidelines ⭐️ANCA status can affect EGPA tx response ⭐️mepolizumab useful for EGPA and HES ⭐️ongoing trial for benralizumab (anti-IL-5R) #ACR21 @RheumNow https://t.co/Xr99nAx5BA

ACR and KL grades for identifying OA @carla_scanzello #ACR21 @RheumNow and New research proposed KOA criteria - updates in OA https://t.co/74j3RrpbG8

While angiographic change thankfully is uncommon in large vessel vasculitis patients it's 3x more likely at a given site if there was been baseline PET/CT activity there. Important step in understanding LVV natural history! @KQuinnRheum @petercgrayson #ACR21 ABST0503 @RheumNow https://t.co/ROjLZyvEj4

So you say LVV is a monophasic disease? Look at these wavy lines, that keep on going up and down over time for both TAK and GCA - dynamic change. The ESR/CRP might get better, but something below there keeps on burning... @KQuinnRheum @petercgrayson #ACR21 ABST0504 @RheumNow https://t.co/sxTR16p6WJ

#ACR21 Abst#0455 ABT improves subclin arthritis in +ACPA pts w/ MRI signs of [teno]synovitis or osteitis per ARIAA study ➡️61% w/ improved MRI findings vs 31% PBO ➡️Arthritis developed in 4 on ABT vs 17 PBO Do you use ABT for early RA? #ACRBest @Rheumnow https://t.co/btfH9lb6TU https://t.co/qOGkxSogZF

• Abatacept Reverses Subclinical Arthritis in Patients with High-risk to Develop …

MAS in sJIA - retrospective multicenter study 147 pts- 2 peds clinics in Turkey. 22% developed MAS median 5 month multiple attacks per pt - highest being 4 51% remined on the same biologic and resulted in improvement @RheumNow #ACR21 #ACRBest #abst0246

Assisted reproductive tech for pts w/ rheum dz is safe for stable/quiescent dz #acr21 ⁦@ACRheum⁩ reproductive guideline ⁦@RheumNow⁩ https://t.co/312EuRSJrB

Fautrel reports mixed response to JAK Inhib. in 8 refractory Adult (6) & juvenile (2)-Onset Still's Dz w/ dz Dz duration 86 mos (7 Systemic, 1 Chr articular) w/ JAKi (Bari 4, Upa1, Tofa 2, Ruxo 2). There were no remissions, 50% had partial response @ 11 mos #ACR21 Abstr#0195 https://t.co/Ww8ONBrRqq

RheumNow’s expanded coverage of the #ACR21 meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow & its Faculty.

#ACR21 #pedsrheum With so much work ahead, what to tackle first? 1⃣Gathering and organizing the top 10 priorities in cSLE https://t.co/H3ASXAfM4m

Rheum Radiology Bootcamp Rheum dz = increased risk of lung cancer Important note: Fleischner recs for incidental nodules do not apply to immunosuppressed patients. Stay on alert for malignancy. #ACR2021